Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intrinsic Bioprobes, a biotechnology company, has started a contract with the National Cancer Institute or NCI to develop effective technologies for accurate measurement of cancer-related proteins and peptides that improve diagnostic capabilities by effectively discerning diseased from non-diseased states. The total cost of the two-and-a-half-year contract is $1.27 million.
Subscribe to our email newsletter
Of the $1.27 million contract, $1.13 million is Federal money provided by the NCI, and $146,088 is the contractor’s share provided by Intrinsic Bioprobes. This contract is in support of NCI’s Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research.
Dobrin Nedelkov, scientific director of Intrinsic Bioprobes, said: “The purpose of this contract is to stimulate the development of multiplex mass spectrometric immunoassay for the detection of low abundance cancer-related proteins/peptides from bodily fluids.
“The multiplex mass spectrometric immunoassays will bridge that gap because they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation. The mass spectrometric aspect of the assays also enables single-step detection of protein isoforms and their individual quantification, which is an important protein diversity aspect regularly overlooked in contemporary proteomics approaches.”